Regeneron Wins FDA Approval for Pasatru in FOP, Enables Home Infusion

For QA directors and regulatory leads managing ultra-rare disease biologics, Regeneron Pharmaceuticals' FDA approval of Pasatru™ (garetosmab-grts) sets a concrete precedent: a fully human monoclonal antibody serving a global diagnosed population of approximately 900 patients can clear a placebo-controlled Phase 3 bar and support home infusion administration, each element carrying distinct GMP and supply-chain obligations.

The approval rests on efficacy and safety data from the OPTIMA trial, a Phase 3 placebo-controlled study in adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder in which heterotopic ossification progressively infiltrates muscles, tendons, ligaments, and connective tissues. At 56 weeks, the 10 mg/kg dose (n=23) reduced new HO lesions by 90% versus placebo (2 vs. 19 lesions by CT scan); the 3 mg/kg dose (n=19) achieved a 94% reduction (1 vs. 19 lesions). Clinician-assessed flare-ups fell 88% in the 10 mg/kg arm. The trial enrolled 63 participants total, a dataset size that reflects the regulatory flexibility applied under rare disease pathways while still demanding rigorous process validation for each manufactured lot.

Pasatru is derived from Regeneron's VelocImmune® platform, a fully human antibody technology. Scaling biologics manufacturing for a patient population of this size introduces specific GMP considerations: batch release criteria, in-process controls, and sterility assurance must be maintained at commercial scale even when annual demand is measured in hundreds of units rather than millions. Lot traceability and deviation management under 21 CFR Part 211 and ICH Q10 quality system requirements apply without modification regardless of indication prevalence.

The home infusion administration option adds a further layer of drug product packaging and cold-chain accountability. The recommended dosing, 10 mg/kg intravenously over 60 minutes once monthly, with a 3 mg/kg alternative if tolerability is a concern, requires that drug product presentations, diluent compatibility, and container-closure integrity support administration outside a controlled clinical setting. Plant heads and packaging teams will need to confirm that primary and secondary packaging specifications, labeling, and cold-chain validation protocols address the full range of approved care settings documented in the prescribing information.

Serious treatment-emergent adverse events occurred in 2 patients in the 10 mg/kg arm, 1 in the 3 mg/kg arm, and 2 on placebo across the 63-participant trial. The most common adverse reactions at or above 10% incidence included abscess, acne, and increased hair growth, a safety profile that will inform pharmacovigilance and post-market surveillance planning under the approved label.

With commercial launch now contingent on supply readiness for a geographically dispersed rare-disease population, the measurable near-term checkpoint is whether Regeneron's manufacturing and distribution infrastructure can sustain monthly intravenous dosing across home infusion networks without cold-chain or lot-release gaps.

Source: Regeneron Pharmaceuticals via GlobeNewswire, August 19, 2026.